NO2020045I1 - Luspatercept - Google Patents

Luspatercept

Info

Publication number
NO2020045I1
NO2020045I1 NO2020045C NO2020045C NO2020045I1 NO 2020045 I1 NO2020045 I1 NO 2020045I1 NO 2020045 C NO2020045 C NO 2020045C NO 2020045 C NO2020045 C NO 2020045C NO 2020045 I1 NO2020045 I1 NO 2020045I1
Authority
NO
Norway
Prior art keywords
luspatercept
Prior art date
Application number
NO2020045C
Other languages
English (en)
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of NO2020045I1 publication Critical patent/NO2020045I1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
NO2020045C 2008-08-14 2020-12-17 Luspatercept NO2020045I1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18909408P 2008-08-14 2008-08-14
PCT/US2009/004659 WO2010019261A1 (en) 2008-08-14 2009-08-13 Use of gdf traps to increase red blood cell levels

Publications (1)

Publication Number Publication Date
NO2020045I1 true NO2020045I1 (no) 2020-12-17

Family

ID=41669153

Family Applications (1)

Application Number Title Priority Date Filing Date
NO2020045C NO2020045I1 (no) 2008-08-14 2020-12-17 Luspatercept

Country Status (21)

Country Link
US (10) US8058229B2 (no)
EP (3) EP3750552B1 (no)
JP (6) JP5922928B2 (no)
AU (1) AU2009282441B2 (no)
CA (1) CA2733911C (no)
CY (3) CY1121971T1 (no)
DK (3) DK2340031T3 (no)
ES (3) ES2949049T3 (no)
FI (1) FI3750552T3 (no)
FR (1) FR20C1066I2 (no)
HR (3) HRP20230761T1 (no)
HU (4) HUE063136T2 (no)
LT (4) LT2340031T (no)
NL (1) NL301082I2 (no)
NO (1) NO2020045I1 (no)
PL (3) PL2340031T4 (no)
PT (3) PT2340031T (no)
SI (3) SI3494986T1 (no)
TR (1) TR201910890T4 (no)
TW (7) TWI784538B (no)
WO (1) WO2010019261A1 (no)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2574777C (en) * 2004-07-23 2015-09-01 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
AU2006213686A1 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
CN103479994B (zh) 2005-11-23 2019-08-30 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) * 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
MX2009008222A (es) * 2007-02-01 2009-10-12 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
TWI667038B (zh) 2007-02-09 2019-08-01 美商艾瑟勒朗法瑪公司 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
TWI454479B (zh) 2007-03-06 2014-10-01 Amgen Inc 變異之活動素受體多肽及其用途
CN103877564A (zh) 2007-09-18 2014-06-25 阿塞勒隆制药公司 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
EP3363453A1 (en) * 2008-06-26 2018-08-22 Acceleron Pharma Inc. Soluble actriia as activin-actriia antagonist for use in treating anemia or bone-related disorders
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
WO2010019261A1 (en) 2008-08-14 2010-02-18 Acceleron Pharma Inc. Use of gdf traps to increase red blood cell levels
RS55369B1 (sr) 2008-11-26 2017-03-31 Amgen Inc Stabilizovana varijanta aktivin iib receptora
US8138142B2 (en) 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
AU2010258931B2 (en) 2009-06-08 2015-04-23 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
CN102656187A (zh) * 2009-06-12 2012-09-05 阿塞勒隆制药公司 截短的actriib-fc融合蛋白
AU2015203400A1 (en) * 2009-08-13 2015-07-16 Acceleron Pharma Inc. Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
KR20180085825A (ko) * 2009-08-13 2018-07-27 악셀레론 파마 인코포레이티드 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용
MX340451B (es) * 2009-09-09 2016-07-08 Acceleron Pharma Inc Antagonistas de actriib y dosificacion y usos de los mismos.
ES2869864T3 (es) * 2009-11-03 2021-10-26 Acceleron Pharma Inc Procedimientos para el tratamiento de la enfermedad del hígado graso
EP2501400B1 (en) * 2009-11-17 2017-11-01 Acceleron Pharma, Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
WO2014121221A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an anti-activin-a compound to a subject
EP2507267B1 (en) * 2009-12-02 2016-09-14 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life of fc fusion proteins
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
ES2671347T3 (es) * 2010-06-21 2018-06-06 Kyowa Hakko Kirin Co., Ltd. Procedimiento para purificar una proteína que utiliza un aminoácido
KR20130132824A (ko) 2010-11-08 2013-12-05 악셀레론 파마 인코포레이티드 Actriia 결합제 및 이의 용도
EP2718328A4 (en) * 2011-06-08 2014-12-24 Acceleron Pharma Inc COMPOSITIONS AND METHODS FOR INCREASING THE HALF TIME OF SERUM
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
KR20220075438A (ko) * 2011-10-17 2022-06-08 악셀레론 파마 인코포레이티드 비효율적 적혈구생성 치료를 위한 방법 및 조성물
JP6177249B2 (ja) 2011-11-14 2017-08-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｇｄｆ８及び／又はアクチビンａに特異的に拮抗することによって筋肉量及び筋力を増加させる組成物及び方法
EP2793925B1 (en) 2011-12-19 2019-03-20 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
JP6214537B2 (ja) * 2012-08-21 2017-10-25 国立大学法人九州大学 貧血患者の貧血の要因を検出するためのバイオマーカー
US20150276766A1 (en) * 2012-10-24 2015-10-01 Celgene Corporation Biomarker for use in treating anemia
AU2013334660B2 (en) * 2012-10-24 2018-08-09 Celgene Corporation Methods for treating anemia
CA2890217C (en) 2012-11-02 2021-07-20 Yifu FANG Activin-actrii antagonists and uses for treating bone and other disorders
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
MA39722A (fr) * 2014-03-21 2021-06-02 Acceleron Pharma Inc Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11
ES2845650T3 (es) * 2014-04-18 2021-07-27 Acceleron Pharma Inc Procedimientos para aumentar los niveles de glóbulos rojos y tratar la drepanocitosis
AP2017009674A0 (en) 2014-06-13 2017-01-31 Acceleron Pharma Inc Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
EP3212213B1 (en) 2014-10-30 2021-04-28 Acceleron Pharma Inc. Methods and compositions using gdf15 polypeptides for increasing red blood cells
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
WO2016090077A1 (en) 2014-12-03 2016-06-09 Celgene Corporation Activin-actrii antagonists and uses for treating anemia
EP3256148A1 (en) 2015-02-12 2017-12-20 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
MA41919A (fr) * 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
AU2016246708B2 (en) 2015-04-06 2020-12-24 Acceleron Pharma Inc. ALK7:actRIIB heteromultimers and uses thereof
US10358476B2 (en) 2015-04-06 2019-07-23 Acceleron Pharma Inc. Single arm type I and type II receptor fusion proteins and uses thereof
MX2017013267A (es) 2015-04-15 2018-08-15 Regeneron Pharma Metodos para aumentar la fuerza y funcionalidad con inhibidores del factor de diferenciacion y crecimiento 8 (gdf8).
PL3286206T3 (pl) 2015-04-22 2021-09-13 Biogen Ma Inc. Nowe hybrydowe białka pułapki na ligand actriib do leczenia chorób powodujących zanik mięśni
MY189601A (en) * 2015-05-13 2022-02-18 Celgene Corp Treatment of beta-thalassemia using actrii ligand traps
MA42160A (fr) 2015-05-20 2018-03-28 Maria Cappellini Procédés de culture de cellules in vitro pour la beta-thalassemie a l'aide de pieges a ligands du recepteur de l'activine de type ii
BR112018007066A2 (pt) 2015-10-09 2018-10-23 Sarepta Therapeutics Inc composições e métodos para tratamento da distrofia muscular de duchene e distúrbios relacionados
EP3370754A4 (en) 2015-11-04 2019-10-23 Acceleron Pharma Inc. METHODS FOR INCREASING ERYTHROCYTE RATES AND TREATING INEFFECTIVE ERYTHROPOISIS
WO2017091706A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
US20170306027A1 (en) 2016-04-06 2017-10-26 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
AU2017296040C1 (en) 2016-07-15 2023-06-22 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
US10688412B2 (en) 2016-07-25 2020-06-23 Cehpalon, Inc. Affinity chromatography wash buffer
AU2017302282B2 (en) * 2016-07-27 2024-07-25 Acceleron Pharma Inc. Methods and compositions for treating myelofibrosis
US11267865B2 (en) * 2016-10-05 2022-03-08 Acceleron Pharma Inc. Variant ActRIIB proteins and uses thereof
CN110678195A (zh) 2016-10-05 2020-01-10 阿塞勒隆制药公司 ALK4:ActRIIB异多聚体及其用途
EP3538128A4 (en) 2016-11-10 2020-07-22 Keros Therapeutics, Inc. ACTIVIN TYPE IIA RECEPTOR VARIANTS AND THEIR METHODS OF USE
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
DK3638243T3 (da) 2017-06-14 2024-10-28 Celgene Corp Fremgangsmåder til behandling af myeloproliferativ neoplasma-forbundet myelofibrose og anæmi
JP7258021B2 (ja) 2017-11-09 2023-04-14 ケロス セラピューティクス インコーポレイテッド アクチビンＩＩａ型受容体変異体を含む医薬組成物
KR20200109330A (ko) 2018-01-12 2020-09-22 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법
EP3758800A1 (en) 2018-03-01 2021-01-06 Regeneron Pharmaceuticals, Inc. Methods for altering body composition
WO2019217715A1 (en) * 2018-05-09 2019-11-14 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
US20230183319A1 (en) * 2020-02-03 2023-06-15 Acceleron Pharma Inc. Variant actriib proteins and uses thereof
US11945856B2 (en) 2022-01-28 2024-04-02 35Pharma Inc. Activin receptor type IIB variants and uses thereof

Family Cites Families (210)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1265208A (en) 1915-09-07 1918-05-07 Edward C Kahn Liquid-fuel burner.
JPH0637520B2 (ja) * 1985-07-03 1994-05-18 味の素株式会社 ポリペプチド
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4973577A (en) * 1986-04-04 1990-11-27 The Salk Institute For Biological Studies FSH-releasing peptides
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
AU8761391A (en) * 1990-09-13 1992-04-15 Children's Hospital Medical Center Of Northern California Method for increasing red blood cell production by treatment with activin or activin-related peptides
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US20050186593A1 (en) 1991-05-10 2005-08-25 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US5885794A (en) * 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
US6162896A (en) * 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
CA2086327A1 (en) 1991-05-10 1992-11-11 Lawrence S. Mathews Cloning and recombinant production of receptor(s) of the activin/tgf- .beta. superfamily
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
ES2127757T3 (es) 1991-06-25 1999-05-01 Genetics Inst Composiciones bmp-9.
US6692925B1 (en) * 1992-11-17 2004-02-17 Ludwig Institute For Cancer Research Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
EP0679163A4 (en) 1993-01-12 1997-07-16 Univ Johns Hopkins Med FACTOR-3 OF GROWTH AND DIFFERENTIATION.
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
DE69433742T2 (de) 1993-05-12 2005-07-07 Genetics Institute, LLC, Cambridge Bmp-10 zusammensetzungen
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5831050A (en) * 1993-06-07 1998-11-03 Creative Biomolecules, Inc. Morphogen cell surface receptor
ATE355369T1 (de) 1993-10-14 2006-03-15 Harvard College Verfahren zur induzierung und zur erhaltung neuronalen zellen
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5658876A (en) * 1994-04-28 1997-08-19 The General Hospital Corporation Activin antagonists as novel contraceptives
US5760010A (en) 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
NZ306767A (en) 1995-04-11 2000-03-27 Univ Johns Hopkins Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems
US6132988A (en) * 1995-10-27 2000-10-17 Takeda Chemical Industries, Ltd. DNA encoding a neuronal cell-specific receptor protein
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US20050244867A1 (en) 1996-03-26 2005-11-03 Human Genome Sciences, Inc. Growth factor HTTER36
US6004780A (en) 1996-03-26 1999-12-21 Human Genome Sciences, Inc. Growth factor HTTER36
US6372480B1 (en) * 1996-04-19 2002-04-16 Mycogen Corporation Pesticidal proteins
PL189756B1 (pl) 1996-10-25 2005-09-30 Searle & Co Polipeptyd ludzkiego agonisty receptora erytropoetyny (EPO), sposób jego wytwarzania i zastosowanie, cząsteczka kwasu nukleinowego, kompozycja, sposób selektywnego namnażania ex vivo erytroidalnych komórek progenitorowych
US6017534A (en) * 1996-11-20 2000-01-25 Ecogen, Inc. Hybrid Bacillus thuringiensis δ-endotoxins with novel broad-spectrum insecticidal activity
US6605699B1 (en) * 1997-01-21 2003-08-12 Human Genome Sciences, Inc. Galectin-11 polypeptides
US6034062A (en) 1997-03-13 2000-03-07 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-9 compositions and their uses
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
WO1999006559A1 (en) 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (gdf) receptors
US6372454B2 (en) 1997-08-29 2002-04-16 Human Genome Sciences, Inc. Nucleic acid molecules encoding Follistatin-3
US6953662B2 (en) * 1997-08-29 2005-10-11 Human Genome Sciences, Inc. Follistatin-3
US7052873B2 (en) 1997-10-03 2006-05-30 Chugai Seiyaku Kabushiki Kaisha Natural human antibody
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
US6440930B1 (en) 1998-09-17 2002-08-27 Eli Lilly And Company Protein formulations
EP1116792B1 (en) 1998-09-22 2007-01-24 Long Yu New human growth differentiation factor encoding sequence and polypeptide encoded by such dna sequence and producing method thereof
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6548634B1 (en) 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
IL142717A0 (en) 1998-10-30 2002-03-10 Genetics Inst Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists
US6238860B1 (en) 1998-11-05 2001-05-29 Dyax Corp. Binding moieties for human parvovirus B19
US6777205B1 (en) 1998-11-06 2004-08-17 Sterrenbeld Biotechnologie North America, Inc. Host cells expressing recombinant human erythropoietin
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
BR0008188A (pt) 1999-01-21 2002-02-13 Metamorphix Inc Inibidores de fator de diferenciação de crescimento e usos para os mesmos
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
AU777783B2 (en) 1999-04-19 2004-10-28 Kyowa Hakko Kogyo Co. Ltd. Proliferation inhibitor for androgen-independent tumor
US6468543B1 (en) * 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
MXPA02004671A (es) 1999-11-12 2004-09-10 Maxygen Holdings Ltd Conjugados de interferon gamma.
JP2003516746A (ja) 1999-12-15 2003-05-20 リサーチ ディベロップメント ファンデーション インヒビン・レセプタとしてのベータグリカン及びその利用法
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
JP4487376B2 (ja) * 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
RU2281116C2 (ru) 2000-05-15 2006-08-10 Ф.Хоффманн-Ля Рош Аг Новая фармацевтическая композиция
US6627424B1 (en) 2000-05-26 2003-09-30 Mj Bioworks, Inc. Nucleic acid modifying enzymes
AU2001269709A1 (en) 2000-07-19 2002-02-05 Eli Lilly And Company Nucleic acids, vectors, host cells, polypeptides, and uses thereof
US6632180B1 (en) 2000-09-07 2003-10-14 John H. Laragh Method for evaluating and treating hypertension
DE10045591A1 (de) 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
US7048949B2 (en) 2000-11-20 2006-05-23 The Board Of Trustees Of The University Of Illinois Membrane scaffold proteins
AU2002236558A1 (en) 2000-12-01 2002-06-11 Regents Of The University Of California Method and composition for modulating bone growth
US20030082233A1 (en) 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
TWI329129B (en) * 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US20040132675A1 (en) 2002-02-08 2004-07-08 Calvin Kuo Method for treating cancer and increasing hematocrit levels
US7294472B2 (en) 2001-03-14 2007-11-13 Caden Biosciences Method for identifying modulators of G protein coupled receptor signaling
US20040121008A1 (en) 2001-03-16 2004-06-24 Keiko Shiraishi Process for producing sustained release preparation
SI2116259T1 (sl) 2001-05-24 2012-11-30 Zymogenetics Inc Taci imunoglobulin fuzijski proteini
AU2001286171B2 (en) 2001-05-25 2008-01-10 Serono Genetics Institute S.A. Human CDNAs and proteins and uses thereof
AUPR638101A0 (en) 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
US6855344B2 (en) * 2001-07-17 2005-02-15 Integrated Chinese Medicine Holdings, Ltd. Compositions and methods for prostate and kidney health and disorders, an herbal preparation
KR101021817B1 (ko) 2001-07-17 2011-03-17 데이진 가부시키가이샤 ＰＰＡＲ δ활성화 작용을 측정하는 것을 특징으로 하는 물질의 선택방법 및 약제
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US6784154B2 (en) * 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
CA3094774A1 (en) 2001-12-06 2003-07-03 Fibrogen, Inc. Use of hif prolyl hydroxylase inhibitors for treating neurological disorders
US20030144203A1 (en) 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
US20060234918A1 (en) 2001-12-19 2006-10-19 Voyager Pharmaceutical Corporation Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
US6998118B2 (en) 2001-12-21 2006-02-14 The Salk Institute For Biological Studies Targeted retrograde gene delivery for neuronal protection
CA2472922A1 (en) 2002-02-11 2003-08-21 Genentech, Inc. Antibody variants with faster antigen association rates
CA2476887A1 (en) * 2002-02-21 2003-09-04 Wyeth Gasp1:a follistatin domain containing protein
US20030219846A1 (en) 2002-02-28 2003-11-27 Pfizer Inc. Assay for activity of the ActRIIB kinase
WO2003087162A2 (en) 2002-04-18 2003-10-23 Mtm Laboratories Ag Neopeptides and methods useful for detection and treatment of cancer
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
JP2006500925A (ja) 2002-08-16 2006-01-12 ワイス Ｂｍｐ−２エストロゲン応答エレメントおよびその使用方法
WO2004034962A2 (en) 2002-10-15 2004-04-29 Celgene Corporation Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
US7261893B2 (en) * 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
AU2002953327A0 (en) 2002-12-12 2003-01-09 Monash University Methods of diagnosing prognosing and treating activin associated diseases and conditions
ATE419846T1 (de) 2003-02-07 2009-01-15 Prometic Biosciences Inc Fettsäuren mittlerer kettenlänge, glyceride und analoga als stimulatoren der erythropoiese
US20070155661A1 (en) 2003-02-14 2007-07-05 The Board Of Trustees Of The Leland Standord Junior University Methods and compositions for modulating the development of stem cells
GB0304424D0 (en) 2003-02-26 2003-04-02 Glaxosmithkline Biolog Sa Novel compounds
US20040197828A1 (en) * 2003-03-26 2004-10-07 Gaddy Dana P. Method for diagnosis and treatment of bone turnover
US20070184052A1 (en) * 2003-05-09 2007-08-09 Lin Herbert Y Soluble tgf-b type III receptor fusion proteins
WO2004108157A2 (en) 2003-06-02 2004-12-16 Wyeth Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
EA015166B1 (ru) 2003-06-16 2011-06-30 Ю-Си-Би Мэньюфэкчуринг, Инк. Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител
WO2005009460A2 (en) 2003-07-25 2005-02-03 Medexis, S.A. Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
ATE443724T1 (de) 2004-01-22 2009-10-15 Merck Patent Gmbh Antikrebs-antikörper mit reduzierter komplementfixierung
US20050197292A1 (en) 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
US7625867B2 (en) 2004-03-26 2009-12-01 Acceleron Pharma Inc. BMP-3 propeptides and related methods
AU2005230854A1 (en) 2004-03-31 2005-10-20 Xencor, Inc BMP-7 variants with improved properties
WO2005113590A2 (en) 2004-05-12 2005-12-01 Acceleron Pharma Inc. Bmp10 propeptides and related methods
AU2005258286A1 (en) 2004-06-24 2006-01-05 Acceleron Pharma Inc. GDF3 propeptides and related methods
CA2574777C (en) 2004-07-23 2015-09-01 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
CN101098854B (zh) 2004-07-23 2012-12-05 恩多塞特公司 二价连接体及其轭合物
WO2006015368A2 (en) 2004-08-05 2006-02-09 The Regents Of The University Of California Molecules with effects on cellular development and function
US7095608B2 (en) 2004-08-12 2006-08-22 Audiovox Corporation Video display mounting system and method
JP2008509927A (ja) 2004-08-12 2008-04-03 ワイス Ｇｄｆ−８阻害剤を使用する、糖尿病、肥満、および心臓血管疾患のための併用療法
WO2006039400A2 (en) 2004-09-29 2006-04-13 Mount Sinai School Of Medicine Of New York University Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis
US20070003576A1 (en) 2004-12-09 2007-01-04 Andrea Gambotto Vaccines for the rapid response to pandemic avian influenza
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
JP5063366B2 (ja) 2005-02-16 2012-10-31 ザ ジェネラル ホスピタル コーポレイション ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用
KR20080003929A (ko) 2005-04-26 2008-01-08 아지노모토 가부시키가이샤 골수 적혈구 전구 세포 분화 촉진제
JP2007099764A (ja) 2005-09-09 2007-04-19 Ajinomoto Co Inc 血糖低下剤
BRPI0616589A2 (pt) 2005-09-28 2011-06-28 Zymogenetics Inc polipeptìdeo, e, métodos para produzir um anticorpo para um polipeptìdeo, para reduzir ou inibir a inflamação e para tratar um mamìfero afligido com uma doença inflamatória
ES2370040T3 (es) 2005-10-07 2011-12-12 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. Vacuna de metaloproteinasa 11 de la matriz.
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
CN103479994B (zh) 2005-11-23 2019-08-30 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US20070149458A1 (en) 2005-12-06 2007-06-28 Amgen Inc. Uses of myostatin antagonists
AU2006326815A1 (en) 2005-12-20 2007-06-28 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase
EP1962835A2 (en) 2005-12-21 2008-09-03 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or h3 receptor antagonist/inverse agonist
WO2007076127A2 (en) 2005-12-22 2007-07-05 Biogen Idec Ma Inc Condensed imidazoles or pyrazoles and their use as transforming growth factor modulators
EP2016423B1 (en) * 2006-01-20 2011-07-13 Beckman Coulter, Inc. Methods of detection of iron deficiency
EP1976377A4 (en) 2006-01-25 2010-06-23 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
KR20080098615A (ko) 2006-02-28 2008-11-11 웰스태트 테러퓨틱스 코포레이션 물질대사 장애의 치료용 화합물
AU2007238705A1 (en) 2006-04-14 2007-10-25 Amgen Inc. Agonist erythropoietin receptor antibodies
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
JP2009536659A (ja) * 2006-05-09 2009-10-15 ヘマクエスト・ファーマシューティカルズ，インコーポレーテッド 血液疾患の治療法
ES2382993T3 (es) * 2006-07-21 2012-06-15 Lyne Laboratories, Inc. Composición líquida de acetato de calcio
GB0615129D0 (en) 2006-07-29 2006-09-06 Univ Cardiff Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7547781B2 (en) * 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008060139A1 (en) 2006-11-17 2008-05-22 Erasmus University Medical Center Rotterdam Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein
WO2008073292A2 (en) 2006-12-08 2008-06-19 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for protecting renal tubular epithelial cells from radiocontrast nephro parhy (rcn)
US20100111852A1 (en) 2006-12-14 2010-05-06 Forerunner Pharma Research Co., Ltd. Anti-Claudin 3 Monoclonal Antibody and Treatment and Diagnosis of Cancer Using the Same
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
SG10201702157QA (en) 2006-12-18 2017-04-27 Acceleron Pharma Inc Activin-actrii antagonists and uses for increasing red blood cell levels
MX2009008222A (es) 2007-02-01 2009-10-12 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
TWI667038B (zh) * 2007-02-09 2019-08-01 美商艾瑟勒朗法瑪公司 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
TWI454479B (zh) 2007-03-06 2014-10-01 Amgen Inc 變異之活動素受體多肽及其用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
US20090017019A1 (en) * 2007-06-01 2009-01-15 Wyeth Methods and compositions for modulating bmp-10 activity
WO2009009059A1 (en) 2007-07-09 2009-01-15 Biogen Idec Ma Inc. Spiro compounds as antagonists of tgf-beta
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
WO2009019504A1 (en) 2007-08-03 2009-02-12 Summit Corporation Plc Drug combinations for the treatment of duchenne muscular dystrophy
GB0715938D0 (en) 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
WO2009025651A1 (en) 2007-08-17 2009-02-26 University Of Maine System Board Of Trustees Biologically active peptide and method of using the same
WO2009035629A1 (en) 2007-09-13 2009-03-19 Ludwig Institute Of Cancer Research Method for modifying cellular immune response by modulating activin activity
CN103877564A (zh) * 2007-09-18 2014-06-25 阿塞勒隆制药公司 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
JP5583591B2 (ja) 2007-11-21 2014-09-03 アムジエン・インコーポレーテツド Ｗｉｓｅ結合抗体及びエピトープ
WO2009114180A1 (en) 2008-03-13 2009-09-17 The General Hospital Corporation Inhibitors of the bmp signaling pathway
JP2011523357A (ja) 2008-05-06 2011-08-11 ジョスリン ダイアビーティス センター インコーポレイテッド 褐色脂肪細胞分化を誘導するための方法および組成物
WO2009137075A1 (en) 2008-05-06 2009-11-12 Acceleron Pharma Inc. Anti-activin antibodies and uses for promoting bone growth
KR20190049912A (ko) * 2008-06-26 2019-05-09 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉａ의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도
EP3363453A1 (en) 2008-06-26 2018-08-22 Acceleron Pharma Inc. Soluble actriia as activin-actriia antagonist for use in treating anemia or bone-related disorders
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
WO2010019261A1 (en) 2008-08-14 2010-02-18 Acceleron Pharma Inc. Use of gdf traps to increase red blood cell levels
US20110293526A1 (en) 2008-11-20 2011-12-01 University Of Southern California Compositions and methods to modulate hair growth
RS55369B1 (sr) 2008-11-26 2017-03-31 Amgen Inc Stabilizovana varijanta aktivin iib receptora
US8138142B2 (en) 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
US8110355B2 (en) 2009-02-20 2012-02-07 GenRemedy, LLC Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
PE20120532A1 (es) 2009-04-27 2012-05-18 Novartis Ag ANTICUERPOS ANTI-ActRIIB
AU2010258931B2 (en) 2009-06-08 2015-04-23 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
CN102656187A (zh) 2009-06-12 2012-09-05 阿塞勒隆制药公司 截短的actriib-fc融合蛋白
KR20180085825A (ko) 2009-08-13 2018-07-27 악셀레론 파마 인코포레이티드 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용
MX340451B (es) 2009-09-09 2016-07-08 Acceleron Pharma Inc Antagonistas de actriib y dosificacion y usos de los mismos.
ES2869864T3 (es) 2009-11-03 2021-10-26 Acceleron Pharma Inc Procedimientos para el tratamiento de la enfermedad del hígado graso
EP2501400B1 (en) 2009-11-17 2017-11-01 Acceleron Pharma, Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
WO2012027065A2 (en) 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
US9595813B2 (en) 2011-01-24 2017-03-14 Soraa Laser Diode, Inc. Laser package having multiple emitters configured on a substrate member
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
EP2726099B1 (en) 2011-07-01 2018-07-25 Novartis AG Method for treating metabolic disorders
KR20220075438A (ko) 2011-10-17 2022-06-08 악셀레론 파마 인코포레이티드 비효율적 적혈구생성 치료를 위한 방법 및 조성물
WO2013063536A1 (en) 2011-10-27 2013-05-02 Acceleron Pharma, Inc. Actriib binding agents and uses thereof
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
CA2853187A1 (en) 2011-10-28 2013-05-02 Paranta Biosciences Limited A method of treating mucus hypersecretion
EP2793925B1 (en) 2011-12-19 2019-03-20 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9663569B2 (en) 2012-06-14 2017-05-30 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Use of blocking agents of bone morphogenic protein (BMP) signalling for the treatment of neuroinflammatory and neurodegenerative diseases
EP2868667B1 (en) 2012-07-02 2019-01-30 Kyowa Hakko Kirin Co., Ltd. Therapeutic agent for anemia including renal anemia and cancer-induced anemia which contains anti-bmp9 antibody as active ingredient
AU2013334660B2 (en) 2012-10-24 2018-08-09 Celgene Corporation Methods for treating anemia
US20150276766A1 (en) 2012-10-24 2015-10-01 Celgene Corporation Biomarker for use in treating anemia
WO2014064292A1 (en) 2012-10-26 2014-05-01 Universite Pierre Et Marie Curie (Paris 6) A method for preventing or treating atrial fibrillation
CA2890217C (en) 2012-11-02 2021-07-20 Yifu FANG Activin-actrii antagonists and uses for treating bone and other disorders
CA2890471C (en) 2012-11-08 2021-07-27 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
WO2014093531A1 (en) 2012-12-11 2014-06-19 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Modulation of myofiber repair by anti-myostatin in strategies with stem cells
US20140220033A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an Anti-Activin-A Compound to a Subject
EP3431592A1 (en) 2013-03-14 2019-01-23 Translate Bio, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
TN2016000057A1 (en) 2013-08-14 2017-07-05 Novartis Ag Methods of treating sporadic inclusion body myositis
EP3084000A4 (en) 2013-12-16 2017-09-20 Paranta Biosciences Limited Method of diagnosis and treatment
EP3094751A4 (en) 2014-01-14 2017-06-07 Santa Maria Biotherapeutics, Inc. Activin inhibitor response prediction and uses for treatment
JP2017510622A (ja) 2014-01-27 2017-04-13 ノバルティス アーゲー 筋萎縮を予測するバイオマーカー、方法および使用
JP6601687B2 (ja) 2014-03-31 2019-11-06 大日本住友製薬株式会社 進行性骨化性線維異形成症の予防剤及び治療剤
ES2845650T3 (es) 2014-04-18 2021-07-27 Acceleron Pharma Inc Procedimientos para aumentar los niveles de glóbulos rojos y tratar la drepanocitosis
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
CN107074931A (zh) 2014-06-13 2017-08-18 圣塔玛丽亚生物疗法公司 经配制的受体多肽和相关方法
AP2017009674A0 (en) 2014-06-13 2017-01-31 Acceleron Pharma Inc Methods and compositions for treating ulcers
MY189601A (en) 2015-05-13 2022-02-18 Celgene Corp Treatment of beta-thalassemia using actrii ligand traps

Also Published As

Publication number Publication date
TW201513879A (zh) 2015-04-16
CY2020043I2 (el) 2021-03-12
HRP20201185T1 (hr) 2020-12-11
JP2022009561A (ja) 2022-01-14
TR201910890T4 (tr) 2019-08-21
HRP20191109T1 (hr) 2019-09-20
LT2340031T (lt) 2019-08-12
DK3750552T5 (da) 2024-08-26
TWI748373B (zh) 2021-12-01
EP2340031A4 (en) 2013-01-09
JP2014224154A (ja) 2014-12-04
FR20C1066I2 (fr) 2023-03-24
JP6968917B2 (ja) 2021-11-17
AU2009282441B2 (en) 2015-01-22
JP2017019860A (ja) 2017-01-26
HUE045456T2 (hu) 2019-12-30
LT3750552T (lt) 2023-06-26
TWI617316B (zh) 2018-03-11
US20200199547A1 (en) 2020-06-25
SI3750552T1 (sl) 2023-10-30
JP7329573B2 (ja) 2023-08-18
EP3750552A1 (en) 2020-12-16
FI3750552T3 (fi) 2023-07-25
US20200199548A1 (en) 2020-06-25
US8361957B2 (en) 2013-01-29
TWI784538B (zh) 2022-11-21
US10377996B2 (en) 2019-08-13
ES2738543T3 (es) 2020-01-23
US20130244324A1 (en) 2013-09-19
NL301082I1 (no) 2020-12-23
US11162085B2 (en) 2021-11-02
PT3750552T (pt) 2023-06-28
JP6649432B2 (ja) 2020-02-19
US20220098559A1 (en) 2022-03-31
JP2020055883A (ja) 2020-04-09
HRP20230761T1 (hr) 2023-10-13
PT2340031T (pt) 2019-07-25
AU2009282441A1 (en) 2010-02-18
CY1123217T1 (el) 2020-11-25
TW201006487A (en) 2010-02-16
PL3750552T3 (pl) 2023-11-06
WO2010019261A1 (en) 2010-02-18
US8058229B2 (en) 2011-11-15
EP2340031B1 (en) 2019-04-24
US9505813B2 (en) 2016-11-29
US20200208124A1 (en) 2020-07-02
SI2340031T1 (sl) 2019-09-30
TW201618807A (zh) 2016-06-01
US20120015877A1 (en) 2012-01-19
JP2018130126A (ja) 2018-08-23
EP3494986A1 (en) 2019-06-12
US20100068215A1 (en) 2010-03-18
DK2340031T3 (da) 2019-07-15
CY2020043I1 (el) 2021-03-12
US11168311B2 (en) 2021-11-09
LTPA2020006I1 (lt) 2021-01-11
PL3494986T3 (pl) 2020-11-16
JP5922928B2 (ja) 2016-05-24
EP3494986B1 (en) 2020-06-03
TW201919685A (zh) 2019-06-01
ES2808139T3 (es) 2021-02-25
ES2949049T3 (es) 2023-09-25
US20170204382A1 (en) 2017-07-20
LT3494986T (lt) 2020-07-10
PT3494986T (pt) 2020-07-14
JP2011530599A (ja) 2011-12-22
TW201803586A (zh) 2018-02-01
HUE063136T2 (hu) 2023-12-28
LTC2340031I2 (lt) 2022-06-27
TW202023602A (zh) 2020-07-01
CA2733911A1 (en) 2010-02-18
PL2340031T3 (pl) 2019-10-31
DK3494986T3 (da) 2020-08-03
PL2340031T4 (pl) 2020-12-28
EP2340031A1 (en) 2011-07-06
US11155791B2 (en) 2021-10-26
DK3750552T3 (da) 2023-07-24
HUE051137T2 (hu) 2021-03-01
TWI626945B (zh) 2018-06-21
TW202135851A (zh) 2021-10-01
CY1121971T1 (el) 2020-10-14
SI3494986T1 (sl) 2020-10-30
US20200165583A1 (en) 2020-05-28
TWI472336B (zh) 2015-02-11
CA2733911C (en) 2019-09-03
EP3750552B1 (en) 2023-05-10
FR20C1066I1 (fr) 2021-03-05
US20200199546A1 (en) 2020-06-25
HUS2000054I1 (hu) 2021-01-28
NL301082I2 (nl) 2021-02-03

Similar Documents

Publication Publication Date Title
NO2020045I1 (no) Luspatercept
DK2370462T3 (da) Glucagon-analoger
BRPI0907376A2 (pt) Fotobiorretador
DK2342317T3 (da) Hængende-dråbe-plade
DE602009000234D1 (de) msignals
DK3444343T3 (da) Polypeptider
FI20085199A (fi) Esikammiojärjestely
BRPI0914649A2 (pt) Piprazolo-quinazolinas
DE602008003972D1 (de) Sitzrücklehnungsmechanismus
DE602008003521D1 (de) Sitzrücklehnungsmechanismus
DK2336132T3 (da) Morpholinpurinderivat
DK2342454T3 (da) Vindkraftanlæg
DK2379557T3 (da) Aminopyrazol-forbindelse
DE602008003970D1 (de) Strahlstromkalibriersystem
BRPI0907522A2 (pt) biarlamidas
BRPI0909634A2 (pt) 2-aminoquinolinas
DE112009000183A5 (de) Sicherheitsvorreiber
DE112009001946A5 (de) Mobelauszugsführung
BRPI0909637A2 (pt) 2-aminoquinolinas
BRPI0907863A2 (pt) pirrolopirimidinacarboxamidas
DE602009000862D1 (de) Gehwagenbremse
AT507449A3 (de) Dämmstoffbefestiger
DE602009001190D1 (de) Gleichstromumrichtervorrichtung
ES1067763Y (es) Dendrometro
DE502008003019D1 (de) Einschraubverschraubung